

**Test Report No.: VX-TR-21-0515**

**Copy No.: 1**

## **DETERMINATION OF THE VIRUCIDAL ACTIVITY (EN 14476) OF CLINIKILL PLATINUM**

Lab No.: VX-150-21-0004  
Sample Name: **Clinikill Platinum**  
Method: EN 14476:2013+A2:2019 (E)

Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area – Test method and requirements (phase 2, step 1)

Client: Bocko Pty Ltd & Flexsky Pty Ltd t\_a Pharmachem  
6/70 Fison Avenue W,  
Eagle Farm,  
4009 Queensland,  
Australia

Sample Receipt Date: 11 March 2021

Report Date: 8 June 2021

Page 1 of 15

Kuala Lumpur, 8 June 2021

**Dr Syazani Suhaimi**  
Microbiologist

## Materials and Method

### Quantitative suspension test for the evaluation of virucidal activity in the medical area according to EN 14476:2013+A2:2019 (E)

- 1. Testing laboratory identification** Viroxy Sdn. Bhd.  
6<sup>th</sup> Floor, Menara RKT  
50300 Kuala Lumpur  
Malaysia
- 2. Sample identification**
  - 2.1 Sample name: Clinikill Platinum
  - 2.2 Batch no.: 115283
  - 2.3 Product appearance: Clear, colourless solution
  - 2.4 Manufacturer: Pharmachem
  - 2.5 Active substances: Benzalkonium Chloride  
Poly(hexamethylene) biguanide
  - 2.6 Sample receipt date: 11 March 2021
  - 2.7 Storage conditions: Room temperature
  - 2.8 Product diluent: Distilled water
- 3. Experimental conditions**
  - 3.1 Testing period: 21 May – 30 May 2021
  - 3.2 Test organism(s): *Human coronavirus*, strain 229E, ATCC VR-740
  - 3.3 Concentration/contact time: 2.00 % / 5 minutes
  - 3.4 Loading: 3.00 g/L bovine albumin solution and 3.00 ml/L sheep erythrocytes
  - 3.5 Test temperature: 20 °C ± 1 °C
  - 3.6 Incubation period: 5 days, 36 °C ± 1 °C

#### 4. Test method and its validation

- 4.1 Testing method: Quantal test
- 4.2 Inactivation method: Immediate dilution  
Molecular sieving using MicroSpin™ S 400 HR

The results of validation test A, B, and C proved the viability of the method in all cases.

#### 5. Test results

The results are stated in Tables A and B.

#### 6. Conclusion

**Clinikill Platinum** showed the required virus reduction of  $\geq 4.0 \log_{10}$  against test strain *Human coronavirus* ATCC VR-740 in accordance with EN 14476:2013+A2:2019 (E) at 2.00 % concentration after 5 minutes under the stated condition. According to the simple acceptance decision rule<sup>†</sup>, there is a minimal risk of false acceptance.

Kuala Lumpur, 8 June 2021

**Dr Syazani Suhaimi**  
Microbiologist

#### 7. Note

Virucidal activity – the capability of a product to produce a reduction in the number of viable viruses belonging to reference strains under defined conditions by at least 4 orders ( $10^4$ ).

$R = V_c/N_a$  = the reduction in viability, or  $\lg R = \lg V_c - \lg N_a$

<sup>†</sup> The decision rule applied is simple acceptance rule with no guard band and up to 50 % risk of false acceptance or rejection. This rule has been determined by the laboratory and agreed with the client prior to testing.


**Table A: Evaluation of the virucidal activity of Clinikill Platinum on test strains according to EN 14476**

**Product: Clinikill Platinum**  
**Loading: 3.00 g/L bovine albumin solution and 3.00 ml/L sheep erythrocytes**

**Test strain: Human coronavirus ATCC VR-740**

Virus control, $V_c$	Cytotoxicity effect, CE
$V_{c1}$ : $6.63 \pm 0.25$ $V_{c2}$ : $6.13 \pm 0.37$	$CE_1$ : $1.50 \pm 0.00$ $CE_2$ : $1.50 \pm 0.00$

Test concentration (%) / contact time (min)	First assay, $N_{a1}$	Second assay, $N_{a2}$	Average reduction
2.00 / 5	$N_{a1}$ : $\leq 1.50 \pm 0.00$ $\lg R_1$ : $\geq 5.13 \pm 0.25$	$N_{a2}$ : $\leq 1.50 \pm 0.00$ $\lg R_2$ : $\geq 4.63 \pm 0.37$	$\lg R$ : $\geq 4.88 \pm 0.32$



**Table B: Control tests and method validation for Table A**

Test strain	Cell susceptibility control	Suppression efficiency control	Reference test for virus inactivation
<i>Human coronavirus ATCC VR-740</i>	A: 6.25 ± 0.33 A <sub>PBS</sub> : 5.50 ± 0.00	B: 6.00 ± 0.38 V <sub>C</sub> : 6.50 ± 0.00	C <sub>30</sub> : ≥4.13 ± 0.25 C <sub>60</sub> : ≥4.13 ± 0.25

**Note**

- TCID<sub>50</sub>: The dilution of the virus suspension that induces a cytopathic effect (CPE) in 50 % of cell culture units
- CPE: The morphological alteration of cells and/or their destruction caused by the cytopathic effect of virus multiplication.
- V<sub>C</sub>: log<sub>10</sub> TCID<sub>50</sub> per ml in the viral test suspension at the beginning and at the maximum contact time
- N<sub>a</sub>: log<sub>10</sub> TCID<sub>50</sub> per ml in the test mixture at the end of the contact time
- CE: The morphological alteration of cells caused by the cytotoxicity effect of the product test solution.
- A: log<sub>10</sub> TCID<sub>50</sub> per ml in the cell susceptibility control as compared to PBS
- B: log<sub>10</sub> TCID<sub>50</sub> per ml in the suppression efficiency control as compared to the virus control
- C: log<sub>10</sub> TCID<sub>50</sub> per ml in the reference test for virus inactivation after 30 and 60 minutes (5 and 15 minutes for vaccinia virus)

**Table C: Summary of the log reductions of the quantitative suspension test according to EN 14476**

Test strain	Test concentration (%) / contact time (min)	Log reduction (TCID <sub>50</sub> /ml)	Associated risk <sup>†</sup>
<i>Human coronavirus</i> ATCC VR-740	2.00 / 5	<b>≥4.88 ± 0.32</b>	Minimal risk of false acceptance

<sup>†</sup> The decision rule applied is simple acceptance rule with no guard band and up to 50 % risk of false acceptance or rejection. This rule has been determined by the laboratory and agreed with the client prior to testing.



**Description: Testing the efficacy of chemical disinfectants and antiseptics (EN 14476)**

Lab No.: VX-150-21-0004  
Test Period: 21 May – 30 May 2021  
Test Report No.: VX-TR-21-0515  
Report Date: 8 June 2021  
Copy No.: 1

Client Name: Bocko Pty Ltd & Flexsky Pty Ltd  
Sample Name: Clinikill Platinum  
Batch No.: 115283  
Sample Receipt Date: 11 March 2021

Bocko Pty Ltd & Flexsky Pty Ltd t\_a Pharmachem  
6/70 Fison Avenue W,  
Eagle Farm,  
4009 Queensland,  
Australia

**Efficacy of Clinikill Platinum against *Human coronavirus*, strain 229E, ATCC VR-740 in a quantitative suspension test at 20 °C according to EN 14476:2013+A2:2019 (E) under dirty condition**

**EXPERT OPINION\***

This expert opinion is based on the test report VX-TR-21-0515 dated 8 June 2021.

The virucidal activity of the disinfectant Clinikill Platinum of Bocko Pty Ltd & Flexsky Pty Ltd t\_a Pharmachem against *Human coronavirus* ATCC VR-740 was investigated by a quantitative suspension test according to EN 14476:2013+A2:2019 (E) under dirty condition (3.00 g/L bovine albumin solution and 3.00 ml/L sheep erythrocytes).

According to this suspension test, a disinfectant or a disinfectant solution at a particular concentration is considered as having virucidal activity if the virus titre is reduced by  $\geq 4 \log_{10}$  (inactivation  $\geq 99.99\%$ ) within the recommended exposure period.

Clinikill Platinum was examined at 20 °C at the concentration of 2.00 % for the exposure time of 5 minutes. After the exposure time the viral reduction exceeded 4  $\log_{10}$ -steps in all assays. According to the simple acceptance decision rule<sup>†</sup>, there is a minimal risk of false acceptance. Therefore, a virucidal activity against for *Human coronavirus* ATCC VR-740 was measured as follows:

Dirty condition      2.00 %      5 minutes

Kuala Lumpur, 8 June 2021

**Dr Syazani Suhaimi**  
Microbiologist

**Dr Peter Cheong**  
Head of Microbiology Laboratories

\* Opinions and interpretations expressed here are outside the scope of SAMM (Laboratory Accreditation Scheme of Malaysia) accreditation.

† The decision rule applied is simple acceptance rule with no guard band and up to 50 % risk of false acceptance or rejection. This rule has been determined by the laboratory and agreed with the client prior to testing.



**Description: Testing the efficacy of chemical disinfectants and antiseptics (EN 14476)**

Lab No.: VX-150-21-0004  
Test Period: 21 May – 30 May 2021  
Test Report No.: VX-TR-21-0515  
Report Date: 8 June 2021  
Copy No.: 1

Client Name: Bocko Pty Ltd & Flexsky Pty Ltd  
Sample Name: Clinikill Platinum  
Batch No.: 115283  
Sample Receipt Date: 11 March 2021

**Appendix 1**

**QAU CERTIFICATE\***

The results stated in test report VX-TR-21-0515 dated 8 June 2021 were compared to the raw data of the tests and checked for correct transfer. No deviations were detected.

Kuala Lumpur, 8 June 2021

**Dr Peter Cheong**  
Head of Microbiology Laboratories

\* Opinions and interpretations expressed here are outside the scope of SAMM (Laboratory Accreditation Scheme of Malaysia) accreditation.

Test procedure accredited according to MS ISO/IEC 17025. The test report shall not be reproduced except in full without the written approval of the laboratory. The test result relates only to the sample stated in the test report. The above analysis is based solely on the sample submitted by the customer. Information on measurement uncertainty is available upon request.



**Appendix 2 Raw data**

<b>Test Method</b>	EN 14476:2013+A2:2019				<b>Titration Method</b>	Quantal test			
<b>Product</b>	Clinikill Platinum				<b>Batch No.</b>	115283			
<b>Product Diluent</b>	Distilled water				<b>Lab No.</b>	VX-150-21-0004			
<b>Test Organism</b>	Human coronavirus, strain 229E, ATCC VR-740				<b>Passage No.</b>	6			
<b>Cell Line</b>	MRC-5 cells, ATCC CCL-171				<b>Passage No.</b>	11			
<b>Interfering Substance</b>	3.00 g/L bovine albumin solution and 3.00 ml/L sheep erythrocytes				<b>Inactivation Method</b>	Immediate dilution			
<b>Test Temperature (°C)</b>	20		<b>Incubation Temperature (°C)</b>		36		<b>Dilution Method</b>		Standard
<b>First Assay Test Date</b>	21/05/2021	<b>Second Assay Test Date</b>	25/05/2021	<b>Analyzed By</b>	SSU	<b>Verified By</b>	PCH		

**Validation and Control Procedures**

Cell Susceptibility Control	Product Concentration	Dilution	Dilution (log <sub>10</sub> )										log <sub>10</sub> TCID <sub>50</sub> /ml	ΔTCID <sub>50</sub> < 1 lg
			1	2	3	4	5	6	7	8	9	10		
			PBS	Without	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0		
2.00 %	1:1000	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	6.25 ± 0.33	
		4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 3 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0				

Suppression Efficiency Control	Product Concentration	Contact Time (minutes)	Dilution (log <sub>10</sub> )										log <sub>10</sub> TCID <sub>50</sub> /ml	[TCID <sub>50</sub> - V <sub>C</sub> ] ≤ 0.5 lg
			1	2	3	4	5	6	7	8	9	10		
			2.00 %	30	t t t t	4 4 4 4	4 4 4 4	4 4 4 4	4 4 0 0	0 0 0 0	0 0 0 0	0 0 0 0		
Virus Control (V <sub>C</sub> )	30	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	6.50 ± 0.00	
		4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0				

Reference Test	Product Concentration	Contact Time (minutes)	Dilution (log <sub>10</sub> )										log <sub>10</sub> TCID <sub>50</sub> /ml	lg R = V <sub>C</sub> - N <sub>a</sub>
			1	2	3	4	5	6	7	8	9	10		
			0.70 % Formaldehyde	30	t t t t	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.		
60	t t t t	0 0 0 0		0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	n.d.	n.d.	2.50 ± 0.00		
Virus Control (V <sub>C</sub> )	0	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	6.50 ± 0.00	
	60	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 3	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	6.63 ± 0.25	
Cytotoxicity Effect (CE)	-	t t t t	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	n.d.	n.d.	2.50 ± 0.00		
		t t t t	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0							

Test procedure accredited according to MS ISO/IEC 17025. The test report shall not be reproduced except in full without the written approval of the laboratory. The test result relates only to the sample stated in the test report. The above analysis is based solely on the sample submitted by the customer. Information on measurement uncertainty is available upon request.

**Appendix 2 Raw data**

**Test Procedure**

	Product Concentration	Contact Time (minutes)	Dilution (log <sub>10</sub> )										log <sub>10</sub> TCID <sub>50</sub> /ml			
			1	2	3	4	5	6	7	8	9	10				
First Assay (Na <sub>1</sub> )	2.00%	5	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	n.d.	n.d.	1.50 ± 0.00	V <sub>C1</sub> - CE ≥ 4  Pass? <b>Yes</b>	
			0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0			0 0 0 0
	Virus Control (V <sub>C1</sub> )	0	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.		6.50 ± 0.00
		5	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	3 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.		6.63 ± 0.25
	Cytotoxicity Effect (CE)	0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.		1.50 ± 0.00

	Product Concentration	Contact Time (minutes)	Dilution (log <sub>10</sub> )										log <sub>10</sub> TCID <sub>50</sub> /ml			
			1	2	3	4	5	6	7	8	9	10				
Second Assay (Na <sub>2</sub> )	2.00%	5	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	n.d.	n.d.	1.50 ± 0.00	V <sub>C2</sub> - CE ≥ 4  Pass? <b>Yes</b>	
			0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0			
	Virus Control (V <sub>C2</sub> )	0	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.		5.75 ± 0.33
		5	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 4	4 4 4 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.		6.13 ± 0.37
	Cytotoxicity Effect (CE)	0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	0 0 0 0	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.		1.50 ± 0.00

Average Reduction (lg R)	Product Concentration	Contact Time (minutes)	First Assay (Na <sub>1</sub> )		Second Assay (Na <sub>2</sub> )		Average Reduction (lg R)
			log <sub>10</sub> TCID <sub>50</sub> /ml	lg R <sub>1</sub> = V <sub>C1</sub> - Na <sub>1</sub>	log <sub>10</sub> TCID <sub>50</sub> /ml	lg R <sub>2</sub> = V <sub>C2</sub> - Na <sub>2</sub>	
	2.00%	5	≤1.50 ± 0.00	≥5.13 ± 0.25	≤1.50 ± 0.00	≥4.63 ± 0.37	≥4.88 ± 0.32

**Note**

- TCID<sub>50</sub>: The dilution of the virus suspension that induces a CPE in 50 % of cell culture units
- CPE: The morphological alteration of cells and/or their destruction caused by the cytopathic effect of virus multiplication. '0' denotes no CPE and '1' (approximately 25 % of cells) to '4' (all cells) denotes the degree of CPE per cell culture units.
- V<sub>C</sub>: log<sub>10</sub> TCID<sub>50</sub> per ml in the viral test suspension at the beginning and at the maximum contact time
- N<sub>a</sub>: log<sub>10</sub> TCID<sub>50</sub> per ml in the test mixture at the end of the contact time
- CE: The morphological alteration of cells caused by the cytotoxicity effect of the product test solution. 't' denotes the presence of cytotoxicity per cell culture units.
- A: log<sub>10</sub> TCID<sub>50</sub> per ml in the cell susceptibility control as compared to PBS
- B: log<sub>10</sub> TCID<sub>50</sub> per ml in the suppression efficiency control as compared to the virus control
- C: log<sub>10</sub> TCID<sub>50</sub> per ml in the reference test for virus inactivation after 30 and 60 minutes (5 and 15 minutes for vaccinia virus)

## Appendix 3 Summary of test description

### 1. Virus and cells

- 1.1. *Human coronavirus*, strain 229E, ATCC VR-740
  - 1.1.1. Passage no.: 6
  - 1.1.2. Cell line: MRC-5 cells, ATCC VR-740
  - 1.1.3. Cell line passage no.: 11
  - 1.1.4. Culture medium: EMEM

### 2. Materials and reagents

- 2.1. Eagle's Minimal Essential Medium (EMEM, Sigma, catalogue no. M3024)
- 2.2. Fetal Bovine Serum (FBS, Sigma, catalogue no. F7524)
- 2.3. Formaldehyde (Merck, catalogue no. 1.0.4003.2500)
- 2.4. Dulbecco's Phosphate Buffered Saline (PBS, Sigma, catalogue no. P3813)
- 2.5. Bovine albumin fraction V (Merck, catalogue no. K49238418733)
- 2.6. Defibrinated sheep blood (Hemostat, catalogue no. DSB100)

### 3. Apparatus and glassware

- 3.1. CO<sub>2</sub> incubator (Mettler, model ICO 105)
- 3.2. Cooling water bath (Mettler, model WNB7 with CDP115)
- 3.3. Inverted microscope (Optika, IM-2)
- 3.4. Vortex<sup>®</sup> mixer (Biosan model Biosan V-1 Plus)
- 3.5. Microtitre plate (NEST)
- 3.6. Tissue culture flask (JET Biofil)

## 4. Test procedure

### 4.1. Preparation of test virus suspension

- 4.1.1. Cell monolayers shall be >90 % confluent before inoculation. Cell lines are selected in accordance with their sensitivity to the test organisms.
- 4.1.2. The test organisms and their stock cultures shall be prepared and kept in accordance with EN 12353:2013 (E).
- 4.1.3. The stock virus suspension is multiplied in an appropriate cell line that produces high titres of infectious viruses for 1 hour at 36 °C with intermittent tilting every 15 minutes.
- 4.1.4. The cells are subjected to 3 freeze/thaw cycles once cytopathic effect (CPE) is observed in 80 % of the cell population.
- 4.1.5. Separate the cells debris is by centrifugation at 400 g<sub>N</sub> for 15 minutes.
- 4.1.6. Aliquot the supernatant containing the test virus suspension and store at -80 °C.

### 4.2. Test Na – Determination of virucidal concentrations

- 4.2.1. Pipette 1 ml of interfering substance into a container of suitable capacity for appropriate mixing.
- 4.2.2. Add 1 ml of the virus test suspension to the container, carefully avoiding the upper part of the sides. Mix well.
- 4.2.3. Add 8 ml of the product test solution to the container.
- 4.2.4. Mix, start a stopwatch at once, and place the container in a water bath controlled at the chosen test temperature.
- 4.2.5. Immediately at the end of the chosen contact time, mix, pipette 5ml of the test mixture (virus suspension, interfering substance, and product test solution) into 4.5 ml ice-cold maintenance medium and put into an ice bath.
- 4.2.6. Within 30 minutes, prepare a series of ten-fold dilutions of this mixture (text mixture and maintenance medium).
- 4.2.7. Transfer 0.1 ml of each dilution into six or eight wells of a microtitre plate containing a confluent (>90 %) cell monolayer without any medium.
- 4.2.8. The last row of six or eight wells will receive 0.1 ml of culture medium and will serve as the cell control.
- 4.2.9. After 1 hour of incubation at 37 °C, 0.1 ml of cell culture medium is added to each well.
- 4.2.10. After incubation, the virus titre is calculated. The reduction of virus infectivity is determined from differences of log<sub>10</sub> virus titres before and after treatment with the product.

### 4.3. Cytotoxicity effect – determination of the morphological alteration of cells caused by the product test solution

- 4.3.1. Mix 1 part of hard water and 1 part of interfering substances with 8 parts of the product test solution.
- 4.3.2. Serial dilutions are prepared in the culture medium and are inoculated into cell monolayers.
- 4.3.3. This test is done in parallel with Section 4.2.
- 4.3.4. Any microscopic changes in the cells are recorded when reading the tests for CPE.
- 4.3.5. If the cytotoxicity is so great that the residual infectivity titre is smaller than the required log<sub>10</sub> TCID<sub>50</sub>, special techniques have to be used, such as molecular sieving or ultrafiltration. Follow the instructions of the manufacturer.

**4.4. Cell susceptibility control A – Verification of the susceptibility of the cells for virus infection is not influenced negatively by the treatment with the product test solution**

- 4.4.1. Comparative virus titrations are performed on cells that have or have not been treated with product test solution to check the reduction of the sensitivity to viruses.
- 4.4.2. 0.1 ml of the lowest apparently non-cytotoxic dilution (no microscopic alteration) of the product test solution or PBS and 0.1 ml of culture medium are distributed onto each of 6 established cell cultures in 96-well microtitre plates.
- 4.4.3. After 1 hour of incubation at 37 °C, the supernatant is discarded.
- 4.4.4. The virus is diluted from  $10^{-1}$  to  $10^{-10}$  and titrated on the treated or untreated cells.
- 4.4.5. Verify according to Section 4.8.

**4.5. Suppression efficiency control B – Immediate dilution method validation**

- 4.5.1. Immediately after preparation of the test mixture in Section 4.2, pipette 5ml of the test mixture (virus suspension, interfering substance, and product test solution) into 4.5 ml of ice-cold maintenance medium.
- 4.5.2. Mix again and start the clock. Incubate the mixture in the ice bath for 30 minutes  $\pm$  10 seconds.
- 4.5.3. Immediately prepare dilutions up to  $10^{-8}$  and titrate the virus.
- 4.5.4. This control is performed in parallel to the test.
- 4.5.5. Verify according to Section 4.8.

**4.6. Reference test for virus inactivation C – Validation of the test system**

- 4.6.1. 2 ml of the test suspension shall be mixed with 8 ml of PBS and 10 ml of 1.4 % (w/v) formaldehyde.
- 4.6.2. Contact times are 30 and 60 minutes.
- 4.6.3. Immediately at the end of the contact time, mix and pipette 0.2 ml of the test mixture into a tube containing 1.8 ml ice-cold maintenance medium followed by a further 10-fold dilution.
- 4.6.4. Leave the mixture in the ice bath.
- 4.6.5. Dilutions up to  $10^{-6}$  are prepared by pipetting the diluted test mixture into another tube containing ice-cold maintenance medium in the ice bath.
- 4.6.6. In exceptional cases, smaller volumes of the reagents and of the test suspension could be used, ensuring that the relative proportions are maintained.
- 4.6.7. The cytotoxic control of the formaldehyde shall be performed according to Section 4.3 whereby 8 ml of 1.4 % (w/v) formaldehyde is used instead of the product.
- 4.6.8. The mixture is further diluted to  $10^{-5}$  in an ice bath.
- 4.6.9. Verify according to Section 4.8.

**4.7. Titration of the virus control**

- 4.7.1. The infectivity of the test suspension shall be determined under test conditions at the beginning of the contact time and at the maximum contact time used in the test.
- 4.7.2. Section 4.2 is repeated by substituting the product test solution with hard water or water for ready-to-use products.
- 4.7.3. Verify according to Section 4.8.

#### 4.8. Verification of methodology

- 4.8.1. The titre of the test suspension (virus control) of at least  $10^8$  TCID<sub>50</sub>/mL is sufficiently high to at least enable a titre reduction of 4 log to verify the method. The detectable titre reduction shall be at least 4 log.
- 4.8.2. Cytotoxicity of the product test solution does not affect cell morphology and growth or susceptibility for the test organism in the dilutions of the test mixtures which are necessary to demonstrate a 4-log reduction of the virus.
- 4.8.3. Comparative virus titration on cells cultures treated with test mixture dilutions and in parallel with PBS (cell susceptibility control) result in a difference of <1 log of virus titre.
- 4.8.4. The difference to the test suspension in the control of efficiency for suppression of products' activity shall be  $\leq 5$ log.
- 4.8.5. The difference between the logarithmic titre of the virus control and the logarithmic titre of the test organism in the reference inactivation test is:
  - 4.8.5.1. Between -5 and -2.5 after 30 minutes and between -2 and -4.5 after 60 minutes for poliovirus
  - 4.8.5.2. Between -3 and -5 after 30 minutes and between -3.5 and -5.5 after 60 minutes for adenovirus
  - 4.8.5.3. Between 0.0 and -2.0 after 30 minutes and between -5 and -2.5 after 60 minutes for parvovirus
  - 4.8.5.4. Between -0.75 and -3.5 after 5 minutes and between -2.0 and  $\geq -4.0$  after 15 minutes for vaccinia virus.

#### 5. Literature

- 5.1. EN 14476:2013+A2:2019 (E): Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of virucidal activity in the medical area – Test method and requirements (phase 2, step 1)
- 5.2. EN 14885:2015 (E): Chemical disinfectants and antiseptics – Application of European Standards for chemical disinfectants and antiseptics
- 5.3. EN 12353:2013 (E): Chemical disinfectants and antiseptics – Preservation of test organisms used for the determination of bactericidal (including Legionella), mycobactericidal, sporicidal, fungicidal and virucidal (including bacteriophages) activity

## Looking to Add More Efficacy Claims?

Call us at +60 (0)3 2630 8888.  
We have over 160 test microorganisms to choose from.

